Maternal and amniotic fluid 17α-hydroxyprogesterone levels during pregnancy: Diagnosis of congenital adrenal hyperplasia in utero

M. Nagamani, Paul G McDonough, J. O. Ellegood, V. B. Mahesh

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

17α-Hydroxyprogesterone levels (17α-OHP) were measured in 70 samples of amniotic fluid and 30 samples of maternal serum obtained at different stages of normal pregnancy and in samples of maternal serum and amniotic fluid from a pregnancy with the fetus affected with congenital adrenal hyperplasia. The mean level of 17α-hydroxyprogesterone in the amniotic fluid from control pregnancies was 133.9 ± 7.6 ng. per 100 ml. (range, 25.1 to 266.6 ng. per 100 ml.). The levels were significantly higher in midpregnancy (157.4 ± 8.4 ng. per 100 ml.) than in late pregnancy (79.2 ± 6.8 ng. per 100 ml.) (p < 0.01). Amniotic fluid 17α-OHP levels in the affected pregnancy were significantly higher than the control levels. Mean maternal 17α-OHP level during early pregnancy and midpregnancy was 259.5 ± 22 ng. per 100 ml. and there was a two- to three-fold increase after 34 wk (672.2 ± 61 ng. per 100 ml.) The maternal 17α-OHP levels in the affected pregnancy were significantly higher than the control levels after 34 weeks, but before 34 weeks, the level was within the range seen in control pregnancies. Measurement of 17α-OHP levels in the amniotic fluid before 24 weeks and maternal serum after 34 weeks can be utilized for the prenatal diagnosis of congenital adrenal hyperplasia.

Original languageEnglish (US)
Pages (from-to)791-794
Number of pages4
JournalAmerican Journal of Obstetrics and Gynecology
Volume130
Issue number7
DOIs
StatePublished - Jan 1 1978

Fingerprint

17-alpha-Hydroxyprogesterone
Congenital Adrenal Hyperplasia
Amniotic Fluid
Mothers
Pregnancy
Serum
Prenatal Diagnosis
Fetus

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Maternal and amniotic fluid 17α-hydroxyprogesterone levels during pregnancy : Diagnosis of congenital adrenal hyperplasia in utero. / Nagamani, M.; McDonough, Paul G; Ellegood, J. O.; Mahesh, V. B.

In: American Journal of Obstetrics and Gynecology, Vol. 130, No. 7, 01.01.1978, p. 791-794.

Research output: Contribution to journalArticle

@article{bed5334ffea3471eb69bb630401fd436,
title = "Maternal and amniotic fluid 17α-hydroxyprogesterone levels during pregnancy: Diagnosis of congenital adrenal hyperplasia in utero",
abstract = "17α-Hydroxyprogesterone levels (17α-OHP) were measured in 70 samples of amniotic fluid and 30 samples of maternal serum obtained at different stages of normal pregnancy and in samples of maternal serum and amniotic fluid from a pregnancy with the fetus affected with congenital adrenal hyperplasia. The mean level of 17α-hydroxyprogesterone in the amniotic fluid from control pregnancies was 133.9 ± 7.6 ng. per 100 ml. (range, 25.1 to 266.6 ng. per 100 ml.). The levels were significantly higher in midpregnancy (157.4 ± 8.4 ng. per 100 ml.) than in late pregnancy (79.2 ± 6.8 ng. per 100 ml.) (p < 0.01). Amniotic fluid 17α-OHP levels in the affected pregnancy were significantly higher than the control levels. Mean maternal 17α-OHP level during early pregnancy and midpregnancy was 259.5 ± 22 ng. per 100 ml. and there was a two- to three-fold increase after 34 wk (672.2 ± 61 ng. per 100 ml.) The maternal 17α-OHP levels in the affected pregnancy were significantly higher than the control levels after 34 weeks, but before 34 weeks, the level was within the range seen in control pregnancies. Measurement of 17α-OHP levels in the amniotic fluid before 24 weeks and maternal serum after 34 weeks can be utilized for the prenatal diagnosis of congenital adrenal hyperplasia.",
author = "M. Nagamani and McDonough, {Paul G} and Ellegood, {J. O.} and Mahesh, {V. B.}",
year = "1978",
month = "1",
day = "1",
doi = "10.1016/0002-9378(78)90010-8",
language = "English (US)",
volume = "130",
pages = "791--794",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "7",

}

TY - JOUR

T1 - Maternal and amniotic fluid 17α-hydroxyprogesterone levels during pregnancy

T2 - Diagnosis of congenital adrenal hyperplasia in utero

AU - Nagamani, M.

AU - McDonough, Paul G

AU - Ellegood, J. O.

AU - Mahesh, V. B.

PY - 1978/1/1

Y1 - 1978/1/1

N2 - 17α-Hydroxyprogesterone levels (17α-OHP) were measured in 70 samples of amniotic fluid and 30 samples of maternal serum obtained at different stages of normal pregnancy and in samples of maternal serum and amniotic fluid from a pregnancy with the fetus affected with congenital adrenal hyperplasia. The mean level of 17α-hydroxyprogesterone in the amniotic fluid from control pregnancies was 133.9 ± 7.6 ng. per 100 ml. (range, 25.1 to 266.6 ng. per 100 ml.). The levels were significantly higher in midpregnancy (157.4 ± 8.4 ng. per 100 ml.) than in late pregnancy (79.2 ± 6.8 ng. per 100 ml.) (p < 0.01). Amniotic fluid 17α-OHP levels in the affected pregnancy were significantly higher than the control levels. Mean maternal 17α-OHP level during early pregnancy and midpregnancy was 259.5 ± 22 ng. per 100 ml. and there was a two- to three-fold increase after 34 wk (672.2 ± 61 ng. per 100 ml.) The maternal 17α-OHP levels in the affected pregnancy were significantly higher than the control levels after 34 weeks, but before 34 weeks, the level was within the range seen in control pregnancies. Measurement of 17α-OHP levels in the amniotic fluid before 24 weeks and maternal serum after 34 weeks can be utilized for the prenatal diagnosis of congenital adrenal hyperplasia.

AB - 17α-Hydroxyprogesterone levels (17α-OHP) were measured in 70 samples of amniotic fluid and 30 samples of maternal serum obtained at different stages of normal pregnancy and in samples of maternal serum and amniotic fluid from a pregnancy with the fetus affected with congenital adrenal hyperplasia. The mean level of 17α-hydroxyprogesterone in the amniotic fluid from control pregnancies was 133.9 ± 7.6 ng. per 100 ml. (range, 25.1 to 266.6 ng. per 100 ml.). The levels were significantly higher in midpregnancy (157.4 ± 8.4 ng. per 100 ml.) than in late pregnancy (79.2 ± 6.8 ng. per 100 ml.) (p < 0.01). Amniotic fluid 17α-OHP levels in the affected pregnancy were significantly higher than the control levels. Mean maternal 17α-OHP level during early pregnancy and midpregnancy was 259.5 ± 22 ng. per 100 ml. and there was a two- to three-fold increase after 34 wk (672.2 ± 61 ng. per 100 ml.) The maternal 17α-OHP levels in the affected pregnancy were significantly higher than the control levels after 34 weeks, but before 34 weeks, the level was within the range seen in control pregnancies. Measurement of 17α-OHP levels in the amniotic fluid before 24 weeks and maternal serum after 34 weeks can be utilized for the prenatal diagnosis of congenital adrenal hyperplasia.

UR - http://www.scopus.com/inward/record.url?scp=0017871014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017871014&partnerID=8YFLogxK

U2 - 10.1016/0002-9378(78)90010-8

DO - 10.1016/0002-9378(78)90010-8

M3 - Article

C2 - 637103

AN - SCOPUS:0017871014

VL - 130

SP - 791

EP - 794

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 7

ER -